The choice of polymyxin B as the antibiotic partner in this combination deserves particular attention. Polymyxins are among the last-resort antibiotics for Gram-negative infections, acting by binding to lipopolysaccharide in the outer membrane and disrupting membrane integrity. Yet their clinical utility has been constrained by nephrotoxicity concerns and, increasingly, by the spread of plasmid-borne resistance genes such as mcr variants that have circulated through livestock and food production systems. An adjuvant that restores or potentiates polymyxin susceptibility could allow lower effective doses of the antibiotic, potentially reducing both the toxic burden on patients and the selective pressure that drives resistance dissemination. The study’s systematic screening across a panel of eight antibiotics, including tetracycline, ciprofloxacin, gentamicin, aztreonam, ceftriaxone, cefotaxime, and doxycycline, provides a rational basis for selecting the most synergistic pairing rather than relying on arbitrary combination choices.

Piceatannol itself brings an interesting pharmacological profile to this partnership. As a hydroxylated analogue of resveratrol, the well-known stilbene of red grape fame, it shares the polyphenolic scaffold that has made these compounds subjects of intense investigation across multiple fields of biomedical research. Its documented antioxidant and anti-inflammatory activities suggest it might offer secondary benefits in the context of intestinal infection, where oxidative and inflammatory damage to the gut epithelium contributes substantially to disease severity. The compound is most abundantly available from passion fruit seeds, though it also occurs in grapes and various other plant sources, raising the possibility of relatively accessible supply chains if therapeutic applications were ever developed. The researchers sourced their material from a commercial supplier and dissolved it in dimethyl sulfoxide for experimental use, maintaining solvent concentrations below one percent to avoid confounding effects on bacterial physiology.

The experimental design reflects careful attention to the distinctive biology of biofilm-associated infection. Rather than relying solely on planktonic growth inhibition, the team employed crystal violet staining to quantify biofilm biomass, a classical method that measures the adherence of bacterial communities to abiotic surfaces. They complemented this with assessments of metabolic viability within the biofilm, recognizing that biomass measurements alone can be misleading when compounds alter matrix production without necessarily affecting cell numbers. The focus on swarming motility is particularly noteworthy. Swarming is a flagellum-dependent form of surface translocation that requires coordinated behavior across bacterial populations, and it is intimately linked to the early stages of surface colonization that precede mature biofilm development. By demonstrating that piceatannol suppresses this motility, the researchers identified a mechanism that operates upstream of biofilm maturation, potentially preventing the establishment of resilient communities before they become entrenched.

The characterization of exopolysaccharide and extracellular protein production adds mechanistic depth to these observations. Exopolysaccharides form the structural backbone of the biofilm matrix, creating the hydrated scaffold within which cells are embedded and protected from external threats. Extracellular proteins contribute to matrix stability, facilitate adhesion, and participate in the communication networks that coordinate community behavior. Reducing the production of both components would be expected to yield a structurally weakened biofilm, one more permeable to antibiotics and more vulnerable to immune clearance. This mechanistic understanding aligns with the observed enhancement of polymyxin B efficacy, since the positively charged polymyxin molecule must physically reach the bacterial outer membrane to exert its lethal effect, and a compromised matrix would facilitate that access.

The murine infection model provides the critical translational bridge from in vitro observations to potential clinical relevance. By assessing bacterial loads in the liver and spleen, the researchers gained insight into systemic dissemination, a key concern in E. coli O157 infections where bacteremia can complicate the clinical course. The evaluation of ileal villous morphology addresses the intestinal pathology that characterizes this infection, since the attachment and effacement lesions that E. coli O157 produces on intestinal epithelium are central to its disease mechanism. Improved villous architecture in treated animals suggests that the combination therapy not only reduced bacterial burden but also mitigated the tissue damage that the infection inflicts on the gut lining. Survival outcomes, the ultimate measure of therapeutic efficacy, showed clear superiority of the combination over either agent alone.

The restriction of the in vitro work to a single reference strain, ATCC 43895 carrying both stx1 and stx2 genes, represents both a strength and a limitation worth considering. This strain is a well-characterized laboratory standard whose behavior is highly reproducible, lending confidence to the mechanistic findings. However, clinical isolates of E. coli O157 display considerable genetic diversity, and their biofilm-forming capacities, motility characteristics, and antibiotic susceptibility profiles can vary substantially. Whether the piceatannol-polymyxin B synergy extends across this diversity remains an open question that future studies will need to address. Similarly, the pharmacokinetic behavior of piceatannol in mammals, including its absorption, metabolism, and distribution to intestinal tissues, will require detailed characterization before any therapeutic application can be contemplated.

The broader significance of this work lies in its contribution to the growing recognition that antivirulence strategies represent a complementary approach to traditional antibiotic development. Rather than seeking to kill bacteria outright, antivirulence agents disarm the mechanisms by which pathogens establish infection and resist clearance. This approach theoretically imposes weaker selective pressure for resistance, since the compound does not directly threaten bacterial survival in the same way that bactericidal antibiotics do. The biofilm context is especially relevant here, as the tolerance that biofilm-resident cells exhibit toward antibiotics stems from their physiological state and protective matrix rather than from acquired resistance genes. Disrupting the biofilm lifestyle itself, as piceatannol appears to do, addresses this distinct form of treatment failure that conventional susceptibility testing fails to capture.

Looking forward, the findings open several avenues for continued investigation. Understanding the precise molecular targets through which piceatannol suppresses swarming motility and matrix production would strengthen the mechanistic foundation and potentially reveal conserved regulatory pathways amenable to broader intervention. Exploring whether the compound synergizes with other antibiotic classes or with non-antibiotic therapeutic modalities could expand its utility. Testing against additional Shiga toxin-producing E. coli serotypes and other biofilm-forming enteric pathogens would clarify the generality of the approach. And establishing appropriate dosing regimens, safety profiles, and potential interactions with the complex intestinal environment will be essential steps toward any translational application. For now, the study stands as a compelling demonstration that natural product chemistry, thoughtfully paired with existing antibiotics, can yield combination strategies that address the multifaceted challenges posed by biofilm-associated foodborne pathogens.

Subject of Research: Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation

Article Title: Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation

Article References: Xu, J., Zhou, Y., Bao, W., Ma, Z., Shang, Z., Zhang, H., Wang, W., Li, B., Bai, Y., & Zhang, J. (2026). Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation. Frontiers in Microbiology, 17, Article 1933569. https://doi.org/10.3389/fmicb.2026.1933569

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1933569

Keywords: Escherichia coli O157:H7, piceatannol, polymyxin B, biofilm, antimicrobial resistance, Shiga toxin, exopolysaccharides, swarming motility, antibiotic adjuvant, murine infection model, Frontiers in Microbiology, enhances

The stakes could hardly be higher. Antimicrobial resistance is one of the most severe public health threats of the twenty-first century. According to the Global Burden of Bacterial Antimicrobial Resistance report cited by the authors, resistance was associated with roughly 4.95 million deaths in 2019, with 1.27 million directly attributable to resistant pathogens. Projections warn that without effective countermeasures, annual deaths linked to bacterial resistance could approach ten million by 2050. Compounding the problem, the pipeline of genuinely novel antibiotics has slowed dramatically, and many compounds in development offer little advantage against Gram-negative bacteria, whose double-layered cell envelope is notoriously effective at excluding drugs.

The intestinal microbiota sits at the heart of this crisis. This complex ecosystem of commensal and symbiotic bacteria supports digestion, immunity, metabolism, and the integrity of the intestinal barrier, but it can also serve as a vast reservoir of resistance genes. Overuse and inappropriate use of antibiotics disturb this balance, a state known as dysbiosis, exerting selective pressure that favors resistant organisms and promotes the horizontal transfer of resistance genes between species. Pathogens such as E. coli, Salmonella species, and Enterococcus faecalis can then exploit this disrupted environment, causing illnesses that range from gastrointestinal distress to life-threatening sepsis. Any intervention that allows lower antibiotic doses, the researchers reason, could help reduce that selective pressure.

Enter Porphyridium purpureum. This red microalga has attracted sustained biotechnological interest because it thrives in both marine and freshwater environments and manufactures an impressive portfolio of bioactive molecules, including sulfated exopolysaccharides, phycobiliproteins, and fatty acids. Its polyunsaturated fatty acids, particularly arachidonic acid and eicosapentaenoic acid, have previously been linked to antimicrobial effects through disruption of bacterial cytoplasmic membranes. Because fatty acids can destabilize the plasma membrane, interfere with the electron transport chain, and impair bacterial enzymatic metabolism, the team suspected that the lipid fraction of the alga might hold untapped therapeutic potential.

To find out, the researchers cultivated the microalga in a fifteen-liter bubble column photobioreactor under tightly controlled conditions: artificial seawater enriched with F/2 medium, a temperature of 25 degrees Celsius, and a twelve-hour light and dark cycle. Biomass was harvested at a standardized optical density and subjected to exhaustive percolation extraction with chloroform, a solvent highly efficient at solubilizing nonpolar lipids. The process yielded a total lipid fraction of sixteen percent of the dry biomass. A parallel extraction protocol, using cold ethanol precipitation and ultrasonication, recovered exopolysaccharides at a yield of 841.7 milligrams per liter of culture.

Gas chromatography coupled with mass spectrometry then revealed the chemical identity of the lipid fraction. After derivatization into fatty acid methyl esters, seven compounds were identified, dominated by methyl palmitate at 42.05 percent, methyl arachidonate at 22.73 percent, and methyl linoleate at 17.91 percent, followed by methyl eicosapentaenoate at 8.64 percent and smaller amounts of methyl oleate, methyl alpha-linolenate, and methyl stearate. This profile, rich in both saturated and polyunsaturated fatty acids, closely matches previous characterizations of the species and underscores its reputation as an exceptional natural accumulator of arachidonic acid, a distinction the authors attribute to the alga’s predominantly omega-6 biosynthetic pathway.

The antimicrobial results delivered an unexpected twist. Tested alone at concentrations from 800 down to 6.25 micrograms per milliliter, neither the lipid extract nor the exopolysaccharides inhibited growth of E. coli, Salmonella enterica serovar Typhimurium, or Enterococcus faecalis in standard broth microdilution assays. But the checkerboard combination assays told a different story. At just 6.25 micrograms per milliliter, the extract lowered the ciprofloxacin minimum inhibitory concentration against Salmonella Typhimurium from 4 to 1 microgram per milliliter, producing a fractional inhibitory concentration index of 0.26, well below the 0.5 threshold that defines synergism. Against E. coli, 12.5 micrograms per milliliter of extract reduced the ciprofloxacin MIC from 4 to 2 micrograms per milliliter, an index of exactly 0.50. No synergism appeared when the extract was combined with ampicillin against E. faecalis, although the authors caution that the different antibiotic used for that Gram-positive organism makes it impossible to attribute the difference solely to cell envelope architecture.

The proposed mechanism centers on membrane chemistry. Polyunsaturated fatty acids, with their multiple double bonds, are more fluid than saturated analogs and interact more readily with bacterial membranes, potentially opening transient channels that allow antibiotics to penetrate the cell interior. Prior studies support this idea: arachidonic acid combined with gentamicin slashed the drug’s MIC against Staphylococcus aureus from roughly 37 to 1.7 micrograms per milliliter, and combinations of eicosapentaenoic or alpha-linolenic acid with neomycin produced similar synergy. Comparable effects have been reported for medium-chain fatty acids paired with levofloxacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. coli. The Brazilian team suggests that the synergy observed here likely reflects the combined action of multiple lipid constituents rather than a single fatty acid, and that the extract may be functioning as an antibiotic adjuvant, a compound with little intrinsic killing power that nonetheless amplifies the effect of a co-administered drug.

Crucially, the extract also demonstrated an encouraging safety profile. In Vero monkey kidney cells exposed for twenty-four hours to concentrations ranging from 200 to 1600 micrograms per milliliter, the fifty percent inhibitory concentration came out at 1149.21 micrograms per milliliter, indicating low cytotoxicity. Dividing that value by the synergistic combination MICs yields selectivity indices of 183.8 against Salmonella Typhimurium and 91.9 against E. coli, far above the threshold of ten typically regarded as a favorable in vitro safety margin. The authors suggest that this selectivity may arise from fundamental differences between bacterial and mammalian cells: eukaryotic membranes contain cholesterol, which stabilizes the bilayer, whereas bacteria rely on peptidoglycan and, in Gram-negative species, an outer membrane rich in lipopolysaccharides and porins whose composition and charge may render them more vulnerable to bioactive lipids.

The work is emphatically preliminary. The assays used single reference strains rather than clinical isolates, the active molecules responsible for the synergy remain unidentified, and the suspected membrane-permeabilizing mechanism has not been directly demonstrated. Susceptibility categories of the tested strains, moreover, did not formally shift, remaining resistant for Salmonella and intermediate for E. coli despite the MIC reductions. Still, the implications are striking. A sustainably cultivable microalga, grown from a single batch in a standard photobioreactor, appears to harbor a lipid cocktail that could make existing fluoroquinolones more potent at lower doses. If subsequent studies isolate the responsible fatty acids, confirm the mechanism, and validate the effect across diverse clinical isolates, the gelatinous red cells of Porphyridium purpureum may find a second career not as a nutritional supplement, but as a chemical ally in the desperate race to preserve the usefulness of the antibiotics we already have.

Subject of Research: Antibiotic adjuvant potential of fatty acids from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria

Article Title: Fatty acid profile and antimicrobial activity of chloroform extracts from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria

Article References: Popiorek dos Santos, N., Baptista, R. M., Kubelka, B. G., Montes D’Oca, M. G., Thais de Lima, J., Bueno, D. T., Leitzke, A. F., & Ramos, D. F. (2026). Fatty acid profile and antimicrobial activity of chloroform extracts from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria. Frontiers in Natural Products, 5, Article 1884549. https://doi.org/10.3389/fntpr.2026.1884549

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1884549

Keywords: Porphyridium purpureum, microalgae, antimicrobial resistance, ciprofloxacin, fatty acids, antibiotic adjuvant, synergy, Salmonella Typhimurium, Escherichia coli, gut microbiota, lipid extract, cytotoxicity

The team began with classical natural-products chemistry. Sophoraflavanone G was isolated and purified using chromatographic techniques, and its identity was confirmed by proton nuclear magnetic resonance spectroscopy, the standard method for verifying the hydrogen framework of an organic molecule. Prenylated flavonoids like sophoraflavanone G carry a hydrophobic isoprenoid side chain attached to a flavonoid core, a structural feature long associated with enhanced membrane activity and, consequently, stronger antimicrobial effects than their non-prenylated relatives. That lipophilic appendage is thought to help the molecule insert itself into bacterial lipid bilayers, disturbing membrane integrity and function. The researchers then evaluated both the antibacterial and the anti-biofilm properties of the purified compound across a panel of bacterial strains, including the well-characterized P. aeruginosa strain PAO1 and Staphylococcus epidermidis DSMZ 3270.

Against Gram-positive bacteria, the compound performed impressively. It exhibited potent inhibitory and bactericidal activity against all tested Gram-positive organisms, with Listeria monocytogenes emerging as the most sensitive, inhibited at a minimum inhibitory concentration of just 0.98 micrograms per milliliter. For a plant-derived molecule, sub-microgram-per-milliliter potency is noteworthy and places sophoraflavanone G among the more active flavonoid antibacterials described in the literature. The finding reinforces a pattern that microbiologists have observed repeatedly: prenylated flavonoids tend to be far more effective against bacteria that lack the protective outer membrane characteristic of Gram-negative organisms. That outer membrane, with its tightly packed lipopolysaccharide layer, acts as a molecular sieve that excludes many hydrophobic compounds, including most flavonoids, before they can reach their targets.

The Gram-negative results bore this out in blunt fashion. Sophoraflavanone G showed no meaningful activity against P. aeruginosa in its planktonic, free-swimming form, with a minimum inhibitory concentration exceeding 1000 micrograms per milliliter. In other words, even at the highest concentration tested, the compound could not stop the growth of suspended Pseudomonas cells. This is not a surprise to anyone familiar with the barriers Gram-negative pathogens present, but it matters for the study’s central question: could the compound still do something useful against P. aeruginosa once that pathogen had settled into a biofilm, the matrix-encased community mode in which bacteria are notoriously tolerant of antibiotics?

The answer was nuanced. At low doses, sophoraflavanone G failed to inhibit P. aeruginosa biofilm formation, and it did not enhance the penetration of tobramycin, an aminoglycoside antibiotic commonly deployed against Pseudomonas infections, into the biofilm matrix. Biofilms resist antibiotics through several cooperating mechanisms: an extracellular polymeric substance matrix that physically retards diffusion, metabolic dormancy of cells deep within the community, and the accumulation of resistance determinants. A compound that cannot breach the planktonic outer membrane barrier was unlikely to loosen this fortress on its own at subinhibitory concentrations. The low-dose combination experiments with tobramycin therefore came back essentially negative, a result the authors report transparently rather than overinterpret.

But at a substantially higher concentration of 1 milligram per milliliter, the picture changed. Sophoraflavanone G significantly improved antibiotic penetration into the established P. aeruginosa biofilm. The compound, in other words, appears to act on the biofilm’s permeability barrier in a dose-dependent manner, even though it cannot kill the organism outright. This kind of adjuvant activity, where a molecule with weak intrinsic antibacterial power potentiates a co-administered antibiotic by opening access routes through the biofilm matrix, is an actively pursued strategy in anti-biofilm drug development. The practical caveat is the concentration required: 1 milligram per milliliter is high for systemic therapy, which is why the authors frame this as a proof of principle and call for further development to improve efficacy against Gram-negative pathogens rather than an immediate clinical recommendation.

Where the compound truly shone was against Staphylococcus epidermidis, a Gram-positive coccus that is a leading cause of device-associated infections. S. epidermidis colonizes catheters, prosthetic joints, heart valves, and other implanted materials, encasing itself in biofilms that shield it from both host defenses and antibiotics. The study found that sophoraflavanone G demonstrated strong inhibitory, disruptive, and biofilm-penetrating effects against this organism, with a clear dose-dependent response. It did not merely prevent new biofilm from forming; it also attacked established biofilms and enhanced the penetration of antibiotics into them. For an organism whose pathogenicity depends almost entirely on its ability to form resilient biofilms on medical devices, a molecule that hits biofilm structure and integrity at multiple stages is a genuinely interesting lead.

The contrast between the two organisms encapsulates a central tension in natural-product antimicrobial research. Sophoraflavanone G is, on the evidence of this study, a potent Gram-positive antibacterial and anti-biofilm agent with a plausible secondary role as a biofilm-disrupting adjuvant against Gram-negative pathogens at high concentrations. Its membrane-active chemistry, conferred by the prenyl group, likely explains both strengths: Gram-positive bacteria expose their cytoplasmic membranes directly to the environment, making them vulnerable, while the Gram-negative outer membrane excludes the compound until concentrations are high enough to force some degree of penetration. Understanding this structure-activity relationship could guide medicinal chemists toward derivatives that retain Gram-positive potency while acquiring the ability to cross the Gram-negative barrier, perhaps by tuning lipophilicity or adding metal-chelating or efflux-pump-inhibiting features.

The work also fits into a broader and increasingly urgent context. Antimicrobial resistance, particularly among biofilm-forming pathogens, poses a serious threat to public health, and the World Health Organization has repeatedly flagged carbapenem-resistant P. aeruginosa as a critical-priority pathogen. Biofilm-associated infections are especially intractable because standard susceptibility testing measures activity against planktonic cells, which dramatically underestimates the drug concentrations needed to clear a biofilm on an implanted device. Plant-derived compounds have historically been a rich source of antimicrobial scaffolds, and prenylated flavonoids in particular have attracted attention for their potency and their capacity to act on bacterial membranes and biofilm matrices in ways that complement conventional antibiotics. Studies like this one, which test both planktonic and biofilm modes and include combination experiments with existing drugs, provide exactly the kind of data needed to prioritize candidates for further development.

The authors, led by Niloofar Zanganeh and Vahid Soheili at Mashhad University of Medical Sciences together with Milad Iranshahy and colleagues, are appropriately measured in their conclusions. They underscore the potential of sophoraflavanone G as a candidate for managing Gram-positive and biofilm-associated infections, particularly those involving S. epidermidis, while explicitly highlighting the need for further development to improve its efficacy against Gram-negative pathogens. The study was funded by the Research Council of Mashhad University of Medical Sciences and formed part of a student thesis, illustrating how academic natural-products laboratories continue to feed the antimicrobial pipeline. Whether sophoraflavanone G itself ever reaches the clinic will depend on pharmacokinetics, toxicity, formulation, and the chemistry needed to overcome the Gram-negative barrier, but as a molecular probe it has already delivered a valuable lesson: the same membrane-disrupting feature that makes a flavonoid lethal to staphylococci can, at the right dose, help antibiotics slip past the defenses of one of medicine’s most stubborn Gram-negative adversaries.

Subject of Research: Antibacterial and anti-biofilm activity of the plant-derived prenylated flavonoid sophoraflavanone G against Pseudomonas aeruginosa and Staphylococcus epidermidis

Article Title: Antibacterial evaluation of sophoraflavanone G from Sophora pachycarpa against Pseudomonas aeruginosa and Staphylococcus epidermidis biofilm

Article References: Zanganeh, N., Hatamian, G., Shakeri, A., Bazzaz, B. S. F., Iranshahy, M., & Soheili, V. (2026). Antibacterial evaluation of sophoraflavanone G from Sophora pachycarpa against Pseudomonas aeruginosa and Staphylococcus epidermidis biofilm. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05564-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05564-3

Keywords: sophoraflavanone G, Sophora pachycarpa, biofilm, Pseudomonas aeruginosa, Staphylococcus epidermidis, antimicrobial resistance, prenylated flavonoid, natural products, tobramycin, Listeria monocytogenes, antibiotic adjuvant, Gram-positive bacteria